DAREEN DARANEE SIRI
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- CARLINVILLE, IL
- NPI
- 1730272998
- Received
- $1,524,072 in 2,134 records, 2019 to 2025 ($1,496,505 general, $27,566 research); ownership interests with $68,475 invested
- As principal investigator
- $4,393,616 of research payments to others in 930 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 406 | $376,990 |
| 2025 | Ownership or investment interest | 1 | $34,237 |
| 2024 | General payment | 320 | $234,819 |
| 2024 | Ownership or investment interest | 1 | $34,237 |
| 2024 | Research payment | 1 | $4,750 |
| 2023 | General payment | 272 | $202,969 |
| 2023 | Research payment | 41 | $22,816 |
| 2022 | General payment | 323 | $258,274 |
| 2021 | General payment | 221 | $134,724 |
| 2020 | General payment | 196 | $109,401 |
| 2019 | General payment | 352 | $179,324 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 306 | $754,876 |
| Consulting Fee | 151 | $406,399 |
| Travel and Lodging | 432 | $168,013 |
| Honoraria | 56 | $118,488 |
| Ownership or investment interest | 2 | $68,475 |
| Food and Beverage | 1,121 | $48,186 |
| Research payment | 42 | $27,566 |
| Education | 24 | $539 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Organon Llc | $2,120 | Consulting Fee | Cash or cash equivalent | VTAMA Drug, Dermatology | 2025 | |
| 2025-12-23 | Consortium of Independent Immunology Clinics, LLC | $17,750 | Consulting Fee (5 payments) | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | GC Biopharma USA, Inc. | $2,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ALYGLO Drug, IMMUNOLOGY | 2025 | |
| 2025-12-12 | GENZYME CORPORATION | $785 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | SANOFI US SERVICES INC. | $10,205 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | SANOFI US SERVICES INC. | $169 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | SANOFI US SERVICES INC. | $106 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | SANOFI US SERVICES INC. | $82 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-12-10 | GENZYME CORPORATION | $699 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-10 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-09 | Incyte Corporation | $3,810 | Consulting Fee | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-12-09 | Incyte Corporation | $317 | Consulting Fee | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-12-08 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-06 | Genentech USA, Inc. | $5,625 | Consulting Fee | Cash or cash equivalent | Xolair Biological, Immunology | 2025 | |
| 2025-12-06 | Genentech USA, Inc. | $647 | Travel and Lodging | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-12-06 | Genentech USA, Inc. | $408 | Travel and Lodging | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-12-06 | SANOFI US SERVICES INC. | $224 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-06 | Genentech USA, Inc. | $170 | Food and Beverage | Cash or cash equivalent | Xolair Biological, Immunology | 2025 | |
| 2025-12-06 | Genentech USA, Inc. | $122 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-12-06 | Genentech USA, Inc. | $118 | Travel and Lodging | Cash or cash equivalent | Xolair Biological, Immunology | 2025 | |
| 2025-12-06 | Genentech USA, Inc. | $73 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-12-06 | Genentech USA, Inc. | $62 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2025 | |
| 2025-12-05 | SANOFI US SERVICES INC. | $421 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-02 | Galderma Laboratories, L.P. | $15 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-02 | Ionis Pharmaceuticals, Inc. | $2 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-11-25 | SANOFI US SERVICES INC. | $1,002 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-21 | Arcutis Biotherapeutics, Inc. | $7,125 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-20 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-19 | GENZYME CORPORATION | $22 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-18 | GENZYME CORPORATION | $2,070 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-14 | Arcutis Biotherapeutics, Inc. | $1,875 | Consulting Fee | Cash or cash equivalent | Zoryve Drug, Dermatology | 2025 | |
| 2025-11-13 | Incyte Corporation | $2,540 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-12 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-12 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-11-11 | Novartis Pharmaceuticals Corporation | $6,500 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-10 | SANOFI US SERVICES INC. | $785 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-09 | SANOFI US SERVICES INC. | $8,243 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-09 | ADMA BioManufacturing LLC | $4,000 | Honoraria | Cash or cash equivalent | 2025 | ||
| 2025-11-09 | ADMA BioManufacturing LLC | $710 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-09 | ADMA BioManufacturing LLC | $660 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-11-09 | Regeneron Healthcare Solutions, Inc. | $93 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-09 | ADMA BioManufacturing LLC | $37 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-09 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-08 | Novartis Pharmaceuticals Corporation | $112 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-08 | Incyte Corporation | $58 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-07 | GlaxoSmithKline, LLC. | $262 | Travel and Lodging | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-07 | ADMA BioManufacturing LLC | $121 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-07 | GlaxoSmithKline, LLC. | $79 | Food and Beverage | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-07 | GlaxoSmithKline, LLC. | $54 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | Ionis Pharmaceuticals, Inc. | $146 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-11-06 | Incyte Corporation | $11 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-06 | Incyte Corporation | $8 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-06 | Pharming Healthcare, Inc. | $8 | Food and Beverage | In-kind items and services | RUCONEST Biological, BIOLOGIC | 2025 | |
| 2025-11-05 | Incyte Corporation | $793 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-11-05 | Incyte Corporation | $120 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-05 | Incyte Corporation | $59 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-05 | GC Biopharma USA, Inc. | $22 | Food and Beverage | In-kind items and services | ALYGLO Drug, IMMUNOLOGY | 2025 | |
| 2025-11-05 | Incyte Corporation | $17 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-05 | Incyte Corporation | $17 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-11-04 | Regeneron Healthcare Solutions, Inc. | $3,146 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-04 | Incyte Corporation | $213 | Travel and Lodging | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-10-31 | Regeneron Healthcare Solutions, Inc. | $8,738 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-31 | Regeneron Healthcare Solutions, Inc. | $3,146 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-31 | Regeneron Healthcare Solutions, Inc. | $704 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-31 | Regeneron Healthcare Solutions, Inc. | $598 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-31 | Regeneron Healthcare Solutions, Inc. | $243 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-30 | Regeneron Healthcare Solutions, Inc. | $77 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-29 | Regeneron Healthcare Solutions, Inc. | $1,231 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-29 | Regeneron Healthcare Solutions, Inc. | $115 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-29 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-28 | GlaxoSmithKline, LLC. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-28 | GlaxoSmithKline, LLC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-28 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-26 | Novartis Pharmaceuticals Corporation | $316 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-26 | Novartis Pharmaceuticals Corporation | $259 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-10-26 | Novartis Pharmaceuticals Corporation | $101 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-25 | Novartis Pharmaceuticals Corporation | $633 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $7,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $1,748 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $1,398 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $1,398 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $873 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $873 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $873 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $524 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $513 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $437 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-24 | Regeneron Healthcare Solutions, Inc. | $400 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-21 | Regeneron Healthcare Solutions, Inc. | $1,748 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-17 | GlaxoSmithKline, LLC. | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-16 | Kowa Pharmaceuticals America, Inc. | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZORYVE Drug, DERMATOLOGY | 2025 | |
| 2025-10-16 | Incyte Corporation | $317 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $8,738 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $3,146 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $1,596 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $849 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $638 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $124 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $42 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-15 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-10 | Regeneron Pharmaceuticals, Inc. | $4,893 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-10 | Regeneron Pharmaceuticals, Inc. | $4,194 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-10 | SANOFI US SERVICES INC. | $1,570 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-10-10 | Regeneron Pharmaceuticals, Inc. | $55 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-10 | Regeneron Pharmaceuticals, Inc. | $35 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-08 | GlaxoSmithKline, LLC. | $1,233 | Travel and Lodging | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-08 | GlaxoSmithKline, LLC. | $121 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-07 | Ionis Pharmaceuticals, Inc. | $3,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-10-07 | Regeneron Healthcare Solutions, Inc. | $1,748 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-07 | ADMA BioManufacturing LLC | $172 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-07 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-10-02 | Novartis Pharmaceuticals Corporation | $3,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-01 | GENZYME CORPORATION | $2,447 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-30 | Regeneron Healthcare Solutions, Inc. | $8,738 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-30 | Ionis Pharmaceuticals, Inc. | $3,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-27 | Pharming Healthcare, Inc. | $126 | Food and Beverage | In-kind items and services | RUCONEST Biological, BIOLOGIC | 2025 | |
| 2025-09-26 | Regeneron Healthcare Solutions, Inc. | $301 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-25 | ADMA BioManufacturing LLC | $158 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-25 | Regeneron Healthcare Solutions, Inc. | $112 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-24 | Regeneron Healthcare Solutions, Inc. | $94 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-20 | Ionis Pharmaceuticals, Inc. | $271 | Travel and Lodging | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-20 | Ionis Pharmaceuticals, Inc. | $50 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-20 | Ionis Pharmaceuticals, Inc. | $50 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-20 | Ionis Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $1,572 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $1,223 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-19 | Ionis Pharmaceuticals, Inc. | $463 | Travel and Lodging | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $349 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-19 | Regeneron Healthcare Solutions, Inc. | $349 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-19 | Ionis Pharmaceuticals, Inc. | $271 | Travel and Lodging | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-19 | Ionis Pharmaceuticals, Inc. | $246 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-19 | Ionis Pharmaceuticals, Inc. | $118 | Travel and Lodging | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-19 | Ionis Pharmaceuticals, Inc. | $75 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $7,340 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $240 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-17 | Regeneron Healthcare Solutions, Inc. | $734 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-17 | Regeneron Healthcare Solutions, Inc. | $209 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $228 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $159 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $144 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $135 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $86 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $60 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $48 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $33 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $30 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $24 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $21 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $13 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $8 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $7 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $3 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-10 | Amgen Inc. | $16 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-09-05 | Regeneron Healthcare Solutions, Inc. | $156 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-05 | Regeneron Healthcare Solutions, Inc. | $45 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-04 | Organon Llc | $1,600 | Honoraria | Cash or cash equivalent | VTAMA Drug, Dermatology | 2025 | |
| 2025-09-04 | Takeda Pharmaceuticals U.S.A., Inc. | $22 | Food and Beverage | In-kind items and services | GLASSIA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-03 | Ionis Pharmaceuticals, Inc. | $35 | Food and Beverage | In-kind items and services | DAWNZERA Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-08-28 | GC Biopharma USA, Inc. | $24 | Food and Beverage | In-kind items and services | ALYGLO Drug, IMMUNOLOGY | 2025 | |
| 2025-08-26 | GENZYME CORPORATION | $2,447 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-26 | Regeneron Healthcare Solutions, Inc. | $175 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-26 | Regeneron Healthcare Solutions, Inc. | $14 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-26 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-21 | GENZYME CORPORATION | $41 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $222 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $39 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-08-20 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-20 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-14 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-14 | Ionis Pharmaceuticals, Inc. | $11 | Food and Beverage | In-kind items and services | DONIDALORSEN Drug, PULMONOLOGY & IMMUNOLOGY | 2025 | |
| 2025-08-13 | Incyte Corporation | $635 | Consulting Fee | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-08-13 | Regeneron Healthcare Solutions, Inc. | $126 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $8,738 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-08-08 | Incyte Corporation | $6,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $259 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $122 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $86 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $79 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-08 | Regeneron Healthcare Solutions, Inc. | $15 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-06 | Regeneron Healthcare Solutions, Inc. | $214 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-06 | Regeneron Healthcare Solutions, Inc. | $214 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-06 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Inflammation | 2025 | |
| 2025-08-03 | Incyte Corporation | $224 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-03 | Incyte Corporation | $51 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-03 | Incyte Corporation | $14 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-03 | Incyte Corporation | $8 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-03 | Incyte Corporation | $7 | Food and Beverage | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-02 | Incyte Corporation | $620 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-02 | Regeneron Healthcare Solutions, Inc. | $108 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-02 | Regeneron Healthcare Solutions, Inc. | $80 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-02 | Regeneron Healthcare Solutions, Inc. | $68 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-02 | Regeneron Healthcare Solutions, Inc. | $44 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-02 | Incyte Corporation | $32 | Travel and Lodging | Cash or cash equivalent | Opzelura Drug, Dermatology | 2025 | |
| 2025-08-02 | Regeneron Healthcare Solutions, Inc. | $10 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-01 | GENZYME CORPORATION | $551 | Travel and Lodging | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 |
The latest 200 records of 2,134.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-08 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $4,894 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-12-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $1,908 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-12-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $1,459 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-12-04 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $2,423 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,362 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-11-05 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $1,807 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-11-05 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $1,479 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-10-23 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $928 | A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF | 2025 |
| 2025-10-17 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,359 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-17 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-17 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,377 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-17 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,377 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-10-14 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $2,257 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-10-09 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $2,505 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-10-02 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $1,585 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-10-02 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $377 | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | 2025 |
| 2025-10-01 | Novartis Pharmaceuticals Corporation | Midwest Allergy Sinus Asthma, SC | $11,356 | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared | 2025 |
| 2025-09-22 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $4,326 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-09-15 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $1,000 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-09-15 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,323 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-15 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-15 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-15 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-09-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $3,590 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-09-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $1,644 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-09-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $1,644 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-09-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $48 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-09-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $3,590 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-09-04 | Incyte Corporation | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $3,590 | A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in | 2025 |
| 2025-09-04 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $2,334 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-09-01 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $135 | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 |
| 2025-08-25 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $2,271 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $2,973 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,413 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-08-21 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $2,706 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | ELIAS RESEARCH ASSOCIATES LLC | $1,500 | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the E | 2025 |
| 2025-08-20 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $975 | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | 2025 |
| 2025-08-20 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $2,350 | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | 2025 |
| 2025-08-20 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $12,255 | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | 2025 |
| 2025-08-06 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $1,980 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-08-01 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES | $175 | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 |
| 2025-07-28 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $2,257 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-07-23 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $2,464 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-07-22 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $4,307 | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 |
| 2025-07-21 | Novartis Pharmaceuticals Corporation | Midwest Allergy Sinus Asthma, SC | $12,910 | A 52-week multicenter, randomized, double-blind, placebo-controlled study to assess efficacy and safety of remibrutinib | 2025 |
| 2025-07-14 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $642 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-07-14 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,413 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-07-14 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-07-02 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $3,669 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-07-01 | Novartis Pharmaceuticals Corporation | Midwest Allergy Sinus Asthma, SC | $237 | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared | 2025 |
| 2025-06-27 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,362 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-06-27 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,362 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-06-27 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-06-27 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-06-27 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-06-20 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $5,089 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-06-19 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $4,270 | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 |
| 2025-06-16 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $2,773 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-06-14 | PFIZER INC. | MIDWEST ALLERGY SINUS ASTHMA SC | $1,000 | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI | 2025 |
| 2025-06-12 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $3,970 | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 |
| 2025-06-03 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $7,902 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-05-22 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $2,412 | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 |
| 2025-05-21 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $2,516 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-05-19 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $10,650 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $2,000 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $7,000 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $1,500 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $14,000 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $500 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $500 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $1,000 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-05-09 | UCB SA | SNEEZE, WHEEZE AND ITCH ASSOCIATES, LLC | $1,500 | A PHASE 1/2A, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE (PART A, PARTICIPANT- AND INVESTIGATOR-BLIND) AND RE | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,359 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,323 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $2,973 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,359 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $642 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $1,323 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $214 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-28 | Regeneron Pharmaceuticals, Inc. | SNEEZE WHEEZE & ITCH ASSOCIATES LLC | $2,706 | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-04-23 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $5,840 | A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA | 2025 |
| 2025-04-23 | Amgen Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $10,880 | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability o | 2025 |
| 2025-04-16 | GlaxoSmithKline, LLC. | SNEEZE WHEEZE ITCH ASSOCIATES | $8,820 | A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE | 2025 |
| 2025-04-10 | Eli Lilly and Company | SNEEZE, WHEEZE & ITCH ASSOCIATES | $1,672 | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITI | 2025 |
| 2025-04-07 | SANOFI US SERVICES INC. | Sneeze Wheeze Itch Associates | $17,022 | An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneo | 2025 |
| 2025-04-03 | ABBVIE INC. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $12,040 | A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in | 2025 |
| 2025-04-01 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES | $135 | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 |
| 2025-04-01 | Takeda Pharmaceuticals U.S.A., Inc. | SNEEZE WHEEZE AND ITCH ASSOCIATES LLC | $2,412 | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 |
| 2025-03-27 | Incyte Corporation | DIRECT HELPERS RESEARCH CENTER | $698 | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Lo | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Carlinville, IL, county Macoupin County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Carlinville, IL | County Macoupin County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 5,480 | 44,350 | 12,694,798 |
| Population, 2020 census P1 | 5,710 | 44,967 | 12,812,508 |
| Median age B01002 | 39.9 | 44.2 | 39.0 |
| Under 18 B01001 | 22.3% | 20.6% | 21.8% |
| 65 and over B01001 | 24.3% | 21.6% | 17.0% |
| Households B11001 | 2,032 | 17,576 | 5,036,449 |
| Foreign born B05002 | 2.4% | 0.9% | 14.7% |
| Median household income B19013 | $57,708 | $70,805 | $83,390 |
| Median family income B19113 | $81,434 | $91,250 | $106,018 |
| Per capita income B19301 | $30,638 | $37,136 | $46,406 |
| Poverty rate B17001 | 20.5% | 13.1% | 11.8% |
| Unemployment rate B23025 | 2.4% | 3.7% | 5.8% |
| Civilian labor force B23025 | 2,294 | 20,790 | 6,652,134 |
| Mean commute (minutes) B08013 | 21.2 | 27.5 | 27.8 |
| Bachelor's degree or higher B15003 | 23.4% | 20.3% | 37.8% |
| Housing units B25001 | 2,245 | 21,139 | 5,457,452 |
| Owner-occupied B25003 | 63.6% | 78.5% | 67.1% |
| Renters B25003 | 36.4% | 21.5% | 32.9% |
| Median home value B25077 | $105,700 | $138,200 | $263,300 |
| Median gross rent B25064 | $824 | $801 | $1,274 |
| White, not Hispanic B03002 | 91.0% | 93.5% | 58.1% |
| Black B03002 | 3.0% | 1.5% | 13.3% |
| Hispanic or Latino B03002 | 3.9% | 1.4% | 18.8% |
| Asian B03002 | 0.4% | 0.3% | 5.9% |
| American Indian and Alaska Native B03002 | 0.3% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Carlinville, IL.
Comments